Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Clinical trial NCT04672330 · COMPLETED

Trial details

NCT number

NCT04672330

Sponsor

RenJi Hospital

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2020-12-01

Primary completion

2023-01-25

Enrollment

16

View on ClinicalTrials.gov